NCT07323914 · Phase 3 · RECRUITING
Clinical Analgesic Management in Dementia
This Phase 3 trial is testing whether oxycodone combined with acetaminophen (sold as Tylex) safely and effectively manages moderate to severe chronic pain in people who already have Alzheimer's disease. It is not studying memory or disease progression — the focus is pain relief. Phase 3 means the drug itself is established, but its use specifically in this population is being formally evaluated. Only 10 participants will be enrolled, so this is a small pilot-scale study.
You may qualify if
- Male or female, aged 50 to 90 years at the time of enrollment.
- Meets the NIA-AA core clinical diagnostic criteria for probable Alzheimer's disease.
- Clinical Dementia Rating - Global Score (CDR-GS) between 0.5 and 2.0, inclusive, and Clinical Dementia Rating - Memory Box (CDR-MB) score ≥ 0.5.
- Diagnosed with chronic pain within 6 months prior to enrollment and considered appropriate for opioid therapy.
- Presence and severity of pain confirmed using PAINAD, MOBID-2, or comparable scales.
- Educational attainment: at least 4-6 years of formal education, or not illiterate.
- If currently receiving psychotropic or cognitive-enhancing medications, the dosage must have been stable for at least 3 months prior to study entry and remain unchanged during the study. Unless otherwise specified, all other permitted concomitant medications (non-AD related) must be stably administered for at least 4 weeks prior to baseline.
- Has a reliable caregiver/companion who can assist with study participation, defined as a person who can support the participant throughout the study and spend at least 8 hours per week with the participant.
- Willing and able to participate in this clinical trial, to maintain the assigned intervention during the study period, and has signed the informed consent form.
You're excluded if
- History of transient ischemic attack (TIA), stroke, or seizure within the past 12 months.
- Presence of any psychiatric diagnosis or symptoms that may interfere with study participation (e.g., hallucinations, major depression, or delusions).
- Known allergy to opioid analgesics.
- Severe visual or hearing impairment.
- Alcohol dependence, substance abuse, or other drug addiction or addictive tendency.
- Current participation in another study related to the treatment of Alzheimer's disease.
- Any other uncontrolled or inadequately treated medical condition (e.g., cardiac, respiratory, gastrointestinal, hepatic, or renal disease), or any condition judged by the investigator to compromise participant safety or interfere with study assessments.
- Any other reason deemed by the investigator to preclude participation in the study.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-01-07